Ann: Investor Presentation, page-43

Hi Mer
Re' Price Sensitive

I think the price sensitive part has something to do with the 2 following statements found within the release:

1.
"Whilst acknowledging the rapid rise in clinical trials involving PD-1 and their combination with other treatments*, a PD-1 B-cell vaccination approach represents a paradigm shift in cancer immunotherapy."
* Tang etal. Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology, 2017

The above statement when read with the following excerpt from the release below is what I believe is the price sensitive part:

2.
"In industry-recognised mouse cancer models (colon cancer), the PD-1 targeting B-cell vaccine is more superior than the gold standard mouse PD-1 monoclonal antibody (used in preclinical model testing for Keytruda and Opdivo)."

I don't believe that the above information has been released prior to this release, the information surrounding the PD-1 B Cell mouse trial results being superior is ground breaking which I interpret as being price sensitive information.
fp